146 related articles for article (PubMed ID: 20592894)
1. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.
Ryu SY; Kim K; Kim Y; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Lee KH; Kim BI
J Korean Med Sci; 2010 Jul; 25(7):1029-33. PubMed ID: 20592894
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET in the management of endometrial cancer.
Chao A; Chang TC; Ng KK; Hsueh S; Huang HJ; Chou HH; Tsai CS; Yen TC; Wu TI; Lai CH
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):36-44. PubMed ID: 16167154
[TBL] [Abstract][Full Text] [Related]
3. [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Wang Q; Hong L; Wang JL; Yue MG; Li HB; Li Y
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):300-3. PubMed ID: 20510085
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic value of
Albano D; Zizioli V; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):87-93. PubMed ID: 30573388
[TBL] [Abstract][Full Text] [Related]
5. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer.
Saga T; Higashi T; Ishimori T; Mamede M; Nakamoto Y; Mukai T; Fujita T; Togashi K; Yura S; Higuchi T; Kita M; Fujii S; Konishi J
Ann Nucl Med; 2003 May; 17(3):197-203. PubMed ID: 12846541
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
8. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
9. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
10. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
11. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
12. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.
Picchio M; Mangili G; Samanes Gajate AM; De Marzi P; Spinapolice EG; Mapelli P; Giovacchini G; Sigismondi C; Viganò R; Sironi S; Messa C
Nucl Med Commun; 2010 Jun; 31(6):506-12. PubMed ID: 20168262
[TBL] [Abstract][Full Text] [Related]
13. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.
Signorelli M; Guerra L; Buda A; Picchio M; Mangili G; Dell'Anna T; Sironi S; Messa C
Gynecol Oncol; 2009 Nov; 115(2):231-5. PubMed ID: 19695685
[TBL] [Abstract][Full Text] [Related]
14. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
15. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma.
Belhocine T; De Barsy C; Hustinx R; Willems-Foidart J
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1132-9. PubMed ID: 12192557
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences.
Plodeck V; Rahbari NN; Weitz J; Radosa CG; Laniado M; Hoffmann RT; Zöphel K; Beuthien-Baumann B; Kotzerke J; van den Hoff J; Platzek I
Eur Radiol; 2019 Jan; 29(1):422-428. PubMed ID: 29980927
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of
Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
